Co-funded by the European Union

EIT Health Open Call for Proposals

Innovation Uptake 2027

Under EIT Health Business Plan 2026 - 2028

EIT Health

Munich| 24 June 2026

www.eithealth.eu

Table of Contents

Change Log

Version	Date	Document	Description
1		Call Document	Initial release of the Call Document
2	06.07.2026	Call Document	Update of the Mandatory Deliverables: Proof of Application Submission for Regulatory Approval and Final Clinical Study Report added.
3	13.07.2026	Call Document	Update of the Mandatory Deliverable description Final Clinical Study title and description (the new title is now Clinical Study / Pilot Report)

Abbreviations

AI	Artificial Intelligence
BP	Business Plan
EIT	European Institute of Innovation and Technology
EIT KPIs	Set of Key Performance Indicators (KPIs) defined by the EIT that reflect the EIT operational objectives for education, entrepreneurship, and innovation. These KPIs are used to measure how effectively a KIC/project meets the objectives of the EIT.
EIT SIA	EIT Strategic Innovation Agenda
FSTP	Financial support to third parties
HE MGA	Horizon Europe Model Grant Agreement
IML	Innovation Maturity Level
IP	Intellectual Property
IVDR	In-Vitro Diagnostic Medical Device Regulations
KIC	Knowledge and Innovation Community
KIC SA	KIC Strategic Agenda
MDR	Medical Device Regulations
PA	Partnership Agreement
WP	Work Package

Definitions

Knowledge Triangle Integration	The EIT is established to complement existing Union and national policies and initiatives by fostering the integration of the knowledge triangle – higher education, research and innovation, and business creation – across the Union.
Horizon Europe Model Grant Agreement	The Horizon Europe Model Grant Agreement (HE MGA) sets out the rights and obligations and the terms and conditions applicable to the implementation of the EIT grant.
Deliverable	Deliverables are tangible or intangible goods or service produced during the project implementation phase. They track the progress made towards a project's objectives and may take the form of a report, document, software product, course, event or any other building block of a project. The deliverables specified need to fully demonstrate the project's achievements and the judicious use of public funds.

1 Call Fact Sheet

Call publication	24 June 2026
Application platform opens	15 July 2026
Deadline for applications	16 September 2026, 16.00 CEST
Evaluation timeline	• Evaluation of proposals start: 17 September 2026 • Notification of final outcome: 09 December 2026
Project implementation timeline	• Signature of agreements (launch): 04 January 2027 • Project start: 01 January 2027 • Project end: 30 March 2028
Maximum EIT funding allocated to this call	• Overall financial amount of up to 5,200,000 EUR available for this Call. • Up to 8 projects may be awarded, subject to the quality of the proposals.
Funding terms	• Maximum funding of 650,000 EUR per awarded project. • Grant will cover up to 50% of the total project costs, up to the maximum funding described above. • Funding to the Commercialising Entity in the case that it qualifies as a micro or small enterprise must be between 400,000 - 500,000 EUR. • Mandatory Financial Sustainability Contribution Agreement to be signed between EIT Health and the Commercialising Entity. • If the Commercialising Entity qualifies as a micro or small enterprise, it must demonstrate a minimum level of financial traction of at least EUR 500,000 in the past 3 years from external funding (revenue, equity, or other dilutive sources). Grants or non-dilutive sources do not count against this threshold.
Scope	EIT Health will co-fund collaborative SME- or industry-led projects that focus on new market entry (either first market deployment, or expansion into a new market) and commercial piloting activities for patient-centered digital medical devices (DMDs) and in-vitro diagnostic devices (IVDDs). Projects should focus on generating robust data to demonstrate economic and commercial viability, and improve market access conditions, through: • **Commercialisation pilots** with prospective partners in the target market(s) to test the solution on a small scale. • **Product usability testing** and adaptations for the local target market(s). • **Go-to-market strategy development**, business model validation, pricing model, commercial partnerships and distribution set-up, etc.

	• **Health economics analysis to generate evidence on cost-effectiveness and economic value to support adoption and reimbursement.** • **Applying for reimbursement pathways**, such as national fast-track programmes selective insurance contracts, or other pathways.
Solution eligibility[1]	• The solution must be a medical device or application as defined in regulations EU 2017/745 (MDR) or EU 2017/746 (IVDR).[2] Products that are currently in transition to MDR or IVDR are also eligible.[3] • The solution must be at an Innovation Maturity Level (IML) of either IML 7 (Validation of Solution) or IML 8 (Approval & Launch) with an obtained CE mark and be preparing for entry into a new market.[4] • At least 2 sides of the Knowledge Triangle (business, education and research) must be represented within the consortium. • The Activity Leader of the consortium must be a Commercialising Entity, responsible for commercialising the solution alone or with a partner.
List of call documents	• Call document • Application form, available on the application platform here • Frequently Asked Questions, available here. • Project implementation handbook, available here • Key Performance Indicators Framework, available here
List of contract templates	• Financial Support Agreement template, available here • Project Grant Agreement, available here • Grant to Options to Equity agreement, available here • Revenue Sharing agreement, available here
How to apply	• **Step 1:** register your organisation in the EU Funding & tender opportunities portal to obtain the nine-digit Participant Identification Code (PIC number). If you do not know if your organisation has a PIC number you can check in the EU Portal - click here • **Step 2:** apply to the call via EIT Health's application platform here.

[1] Please see the full scope of eligibility conditions listed in chapter three; Conditions to Receive Funding.
[2] https://eur-lex.europa.eu/eli/reg/2017/745/oj/eng and https://eur-lex.europa.eu/eli/reg/2017/746/oj/eng
[3] This includes devices that have been CE marked under the previous Directives 93/42/EEC (MDD) or 98/79/EC (IVDD) and that continue to be lawfully placed on the market under the applicable transitional provisions. Where such products are required to update their CE marking under MDR or IVDR within the legally established transition timelines, they shall remain eligible for this call, provided that:
- their CE certificate under MDD or IVDD remains valid,
- they comply with the applicable transitional provisions of MDR or IVDR, and
- they are in the process of obtaining CE marking under the current Regulations.

[4] Please refer to EIT Health's Healthcare Innovation Cycle Framework for more information on the required Innovation Maturity Level for this call: https://eithealth.eu/a-framework-for-innovation-in-healthcare/

Further information to interested applicants	• **Call introduction webinar**: 15 July 2026, 12:30 CEST**.** Click here to register. • **Open Q&A session:** 01 September 2026, 11:00 CEST, Click here to register.
Contact	Calls@eithealth.eu

2 Introduction

EIT Health is a Knowledge and Innovation Community (KIC) of the European Institute of Innovation and Technology (EIT), an EU body operating under the Horizon Europe framework. Our mission is to strengthen a sustainable healthcare system in Europe by accelerating innovation and building future health leaders (see chapter 10 and 11 for more information).

Advanced technology, data utilisation and Artificial Intelligence (AI) are driving the shift towards digital healthcare to improve the efficiency and effectiveness of medical services while driving better healthcare outcomes for patients. The successful digital transformation of healthcare systems in Europe, including the implementation of the European Health Data Space, requires the adoption at scale of proven, trustworthy and market-ready digital health solutions by healthcare professionals and institutions.

EIT Health's Innovation Uptake Call will support projects that aim to accelerate the market roll-out, commercialization and uptake of patient-centered digital- and AI-powered healthcare innovations such as digital medical devices and diagnostic solutions that are clinically validated and regulated (i.e. CE mark obtained, initial traction demonstrated, etc.), across one or several EU markets.

Funded projects are expected to leverage capabilities from across the "Knowledge Triangle", bringing together a consortium of partners from education, research and business to carry out activities related to the market deployment, pricing strategy, execution of commercial pilots and engagement of relevant commercial partners and healthcare providers, including training and upskilling of healthcare professionals, to ensure the solution's viability and scalability in one or several target markets.

EIT Health encourages the participation of entities from the EIT Regional Innovation Scheme (EIT RIS Regions) with the goal of improving the Knowledge Triangle integration and the innovation capacity of local ecosystems in RIS countries and regions.

The European Commission is committed to promoting gender equality in innovation and technology. EIT, as a body of the European Union and an integral part of Horizon Europe, and EIT Health share the EIT KIC gender diversity value statement. Consequently, the gender requirements in Horizon Europe are of significant importance for all EIT Health supported and funded activities, including the ones in this call for proposals.

3 Description of the Call Objectives and Scope

3.1 Project Description

The Innovation Uptake Call invites organisations from across the Knowledge Triangle (Industry, Education and Research) to submit applications for funding for collaborative projects focused on patient-centric digital health solutions starting at Innovation Maturity Level (IML) 7 - Validation of Solution.[5]

Proposed solutions must go beyond the state-of-the-art, have a clear medical purpose, and meet the definition of a digital medical device or in-vitro diagnostics device according to European regulations MDR 2017/745 and IVDR 2017/746. Proposals must address a critical, unmet healthcare need and harness digital technologies. They should demonstrate tangible health outcomes to patients across one or more stages of the patient care pathway, whether through screening, diagnosis, treatment and/or monitoring.

These devices could include software intended to be used alone or in combination with hardware (e.g. scanners, sensors, monitors, etc.) and include static and self-learning algorithms (e.g. artificial intelligence, machine learning). They can be used by patients, caregivers, healthcare professionals and health system users in the broadest sense.

The following types of innovations are out of scope:

- A non-medical device or application.
- A product primarily designed for wellness or lifestyle purposes that can be used without medical oversight.
- A solution that does not directly address medical conditions or treatments.
- A healthcare management software that does not directly impact patient diagnosis, treatment, or care.

These innovations should have already obtained formal regulatory approval (e.g. CE mark) and demonstrated some early market traction. They should now be at the stage of running real-world commercial pilots, building partnerships and generating additional robust evidence. This evidence can be used to demonstrate the solution's relevance in the target market, demonstrate economic and commercial viability, test market access conditions, usage, and adoption by healthcare providers, patients and payors.

As such, project proposals should focus on the following activities:

[5] Please refer to EIT Health's Healthcare Innovation Cycle Framework for more information on the required Innovation Maturity Level for this call: https://eithealth.eu/a-framework-for-innovation-in-healthcare/

- Commercialisation pilots with one or several potential partners (e.g. health care providers, medical device and health technology companies, etc.) to test the implementation of the solution on a small scale and generate the necessary evidence to secure commercial commitments and deploy the product into the target market.
- Usability testing and product adaptations for the target market (e.g. language, user interface, systems integrations, etc.) before a larger scale launch.
- Go-to-market and business model validation activities (e.g. market analysis, establishing commercial or distribution networks, pricing model, etc.) to ensure the deployment of a commercially sustainable solution in the new target market(s). The activities are expected to lead to the product's commercialisation in the new target market(s) within a maximum of one year after the end of the EIT Health funding period.
- Health Economics Studies and preparing evidence prior to or for the purpose of a Health Technology Assessment
- Exploring and setting up reimbursement pathways, for example by applying for national fast-track procedures (DiGA, PE-CAN, etc.) or establishing selective insurance contracts.

The funding of pivotal clinical trials to establish evidence of the solution's safety and efficacy is not eligible. However, funding clinical studies or leveraging ongoing clinical studies to generate clinical and economic evidence for the purposes listed above (e.g. as part of a small-scale pilot or to fulfil the requirements of the local target market) can be included in the project scope. In this case, obtaining all relevant ethical approvals is required and must be demonstrated as part of the project deliverables.

The funded innovation must be based on a viable existing or future business model, backed by robust Intellectual Property Rights and a legally registered, for-profit entity (e.g. a micro, small, medium or large enterprise) acting as the Activity Leader of the project and with the proper capabilities, governance model, partnership agreements and incentives in place to market and scale the solution.

3.2 Project Duration and Expected Impact

Projects should last maximum 15 months. All funded projects under this Call are expected to generate the following outcomes and long-term impact.

- An innovative solution is launched on the market, generating at least 10,000 EUR in sales revenues within one year after the end of the project.
- The solution benefits at least 150,000 European patients and citizens within three years after the end of the project.

Proposals must clearly and credibly articulate the path to achieving such impact, which may be reported up to several years after the end of the EIT Health funding period. Please refer to sections 3.3.3 on Key Performance Indicators (KPIs) and 4.8 on Monitoring for more information on the contractual obligations of projects to report achieved impacts during and after the project funding period.

Extension or continuation of projects will be tied to the conditions described in section 4.9 Fast Track Mechanism and Additional Project Funding.

3.3 Project Design

All proposals must include a comprehensive workplan describing all the required work packages and tasks to successfully carry out the project and achieve the target outcomes. This workplan should demonstrate how the consortium will work towards finalising the technical development, ensuring broad clinical validation, securing regulatory approval and strengthening the market and commercial readiness of the solution.

The plan shall be structured into Work Packages (WPs), each containing clearly defined tasks, milestones, outputs, deliverables, and associated KPIs. Projects will be required to report to EIT Health on the performance of the project (see section 4.8.1). Activity Leaders are asked to report the progress of their deliverables, milestones and KPIs, along with submitting cost reports to ensure eligibility of costs.[6] See section 4.8 for more information on project monitoring.

The organisation and distribution of WPs, tasks, and responsibilities are at the discretion of the consortium according to their specific objectives and methodology. Work plans must be coherent, credible, and results oriented. EIT Health mandates certain deliverables and KPIs. These deliverables and KPIs must be included and fully described in the proposal to be considered for funding.

3.3.1 Activities and Work Packages

Project workplans should aim to describe planned activities in as much detail as possible and can be broken down into as many WPs and include as many sub-tasks as relevant to the project.

The table overleaf is an example of the types of WPs and tasks that EIT Health could expect. This list is provided for illustrative purposes only. Applicants are encouraged to build a workplan that is tailored to their specific project context, activities and needs, and to include those WPs and tasks that are considered relevant to the effective execution of their project.

All work packages must have associated tasks, milestones and deliverables, the achievement of which will be assessed at each reporting period. Projects may include as many tasks, milestones and deliverables as are relevant to the workplan.

[6] https://eithealth.eu/wp-content/uploads/2024/08/EIT-Health_Implementation-handbook.pdf

Example Work Packages and Tasks for projects funded under the Innovation Uptake Call:

WP #	WP Name	Task Name
1	Project Management	• Organisation of consortium meetings. • Coordination of project operations.
2	Execution of commercialisation pilot(s) in healthcare settings	• If required, submission of a Study Initiation Package and obtention of Ethical Approval by relevant Ethics Committee(s). • Onboarding of participating healthcare providers, engagement of key stakeholders and training to healthcare professionals. • Patient recruitment and access to GDPR-compliant health data. • Study activities coordination and collection of data.
3	Product adaptations to target market(s) requirements	• IT integrations and verification testing – security, performance, interoperability, etc. • Solution usability testing and user feedback collection • Commercial product iterations, adaptations, local language translation, etc.
4	Health economics analysis	• Health economics analysis; cost and outcome estimation, scenario and sensitivity analysis.
5	Regulatory and Reimbursement Strategy	• Ensure compliance with requirements of the target market. • Compilation and submission of evidence dossier in the context of a Health Technology Assessment or other reimbursement application. • Negotiation of selective insurance contracts. • Application to national fast-track reimbursement pathways for digital health solutions.
6	Go-to-Market Activities	• Market analysis including segmentation, competitive analysis, stakeholder mapping. • Definition and validation of value proposition, pricing model and commercial offering. • Engagement of stakeholders/KOLs and targeted marketing efforts. • Business & operational model validation. • Sustainable scaling strategy definition.
7	Communication, Dissemination and Exploitation	• Communication and dissemination activities for sharing the innovation with the scientific community, industry, commercial players, civil society and policymakers. • Exploitation activities such as using results in developing, creating and marketing or improving a product, process, or service, or shaping a

		policy that could have a positive impact on the quality of life of European citizens.

3.3.2 Mandatory Deliverables

The deliverables listed in the table below should be included or covered by the project proposal unless otherwise justified. Applicants are free to name deliverables, split them into several sub-deliverables, assign them to the most appropriate Work Package, set the delivery date, and include as many additional relevant deliverables as they see fit.

#	Deliverable	Definition
1	**Ethical Approval Certificate**	Approval from an Ethics Committee to conduct study activities for any clinical site involved in the project, if and where relevant.
2	**Data Management Plan (DMP)**	A preliminary plan outlining how project data will be collected, stored, processed, and shared, ensuring compliance and traceability from the start of the project.
3	**Study initiation package**	A set of documents prepared prior to enrolment of the first study participant, including the clinical study registration number in a WHO-compliant registry and all required regulatory and ethics (and, where applicable, institutional) approvals for initial participant enrolment (for multicentre studies, approvals for the first site are sufficient).
4	**Communication, Dissemination and Exploitation Plan**	A plan outlining key actions, audiences, channels, and communication strategies to disseminate project results, as well as an IP and sustainability exploitation plan.
5	**Market Analysis and Strategy Report**	Comprehensive analysis outlining the go-to-market strategy and scalable business model for the solution in the target market including market sizing and segmentation, competitive analysis, engagement of stakeholders and channel partners, value proposition, and pricing strategy.
6	**Clinical Study/Pilot Report**	Report on the completion of the clinical study and/or pilot activities, including analysed results and, where applicable, the status of posting results in the relevant registry/ies.
7	**Proof of Application Submission for Regulatory Approval**	Proof of submission of regulatory approval dossier to notified body or competent authority.

3.3.3 Key Performance Indicators (KPIs)

All proposals must include a clear KPI plan describing how each KPI will be achieved, monitored, and reported. KPIs must be quantifiable and time bound.

The following KPIs and minimum KPI targets are mandatory and must be included in the proposal. Proposals may include other KPIs from the EIT Health catalogue of KPIs or include additional custom KPIs.

KPI	Definition	Expression	Min. Target	Timeline	Note
EITHE02.4 – Innovation Launched to the Market	Number of innovations launched to the market generating at least EUR 10,000 in sales revenue.	Units (1 Innovation = 1 unit)	1	From project start until 1 year after the end of the funding period.	Projects targeting multiple countries may report more units.
EITHE06.1 – Investment Attracted	Total amount of investment raised from public or private sources	Euros	500,000 EUR	From project start until 3 years after the end of the funding period.	Mandatory if the Commercialising Entity is a micro or small enterprise, otherwise optional.
KIC13 – Patients and Citizens Benefiting from the Solution	Number of end users (patients or citizens) who benefit from the implemented solution.	Units (1 Patient or citizen = 1 unit).	150,000	Within 3 years post-funding.	

The KPIs in the table below are optional, however we encourage applicants to include them in their proposal where possible and relevant to the project:

KPI	Definition	Expression	Min. Target	Timeline	Note
EITHE01.1 – Intellectual Property Rights	Number of IP assets filed or registered (patents, trademarks, copyrights, trade secrets, etc.).	Units	1	Achievable and reportable during the funding period	*N/A*

4 Call Criteria

Following the deadline for submission; admissibility, eligibility, exclusion and selection criteria checks will be performed for each proposal in line with the following criteria. Only proposals satisfying all the admissibility and eligibility criteria shall pass on to the evaluation and selection stages.

4.1 Application Admissibility

Only proposals satisfying all the admissibility criteria below shall pass on to the eligibility criteria assessment stage.

- Applications must be submitted before the call deadline. Any proposals submitted after the deadline will be inadmissible.
- Applications must be submitted using the forms provided inside the electronic submission system. Applications submitted through other means will be inadmissible.
- Applications must use a valid Participant Identification Code (PIC code).
    - To obtain a PIC code, register your organisation in the EU Funding & tender opportunities portal to obtain the nine-digit Participant Identification Code (PIC number). If you do not know if your organisation already has a PIC Code, you can verify directly on the EU Portal (click here) whether your organisation is already registered.
- All upload templates provided in the application platform must be used and unaltered. Uploads that do not use the templates where provided will be inadmissible.

4.2 Application Eligibility Conditions

Only proposals complying with all the following conditions will be considered eligible and move to the external evaluation stage.

4.2.1 Entities eligible to participate

Any legal entity, regardless of its place of establishment, including legal entities from non-associated third countries is eligible to participate without receiving funding, provided that the conditions laid down in the Horizon Europe Regulation have been met (e.g. the entity is not under EU sanction), along with any other conditions laid down in this call.

For this call, a 'legal entity' means a legal entity created and recognised as such under national law, EU law or international law, which has legal personality and which may, acting in its own name, exercise rights and be subject to obligations, or an entity without legal personality.

4.2.2 EU Restrictions on Participation

- **EU restrictive measures** - Entities subject to EU restrictive measures under Article 29 of the Treaty on the European Union (TEU) and Article 215 of the Treaty on the Functioning of the

EU (TFEU)7 as well as Article 75 TFEU8, are not eligible to participate in any capacity, including as beneficiaries, affiliated entities, associated partners, third parties giving in-kind contributions, subcontractors or recipients of financial support to third parties (if any).

Special rules also apply to entities covered by Commission Guidelines No 2013/C 205/0522[9].

- **Legal entities established in Russia, Belarus, or in non-government-controlled territories of Ukraine -** Given the illegal invasion of Ukraine by Russia and the involvement of Belarus, there is currently no appropriate context allowing the implementation of the actions foreseen in this programme with legal entities established in Russia, Belarus, or in non-government-controlled territories of Ukraine. Therefore, even where such entities are not subject to EU restrictive measures, such legal entities are not eligible to participate in any capacity. This includes participation as beneficiaries, affiliated entities, associated partners, third parties giving in-kind contributions, subcontractors or recipients of financial support to third parties (if any). Exceptions may be granted on a case-by-case basis for justified reasons.

  With specific regard to measures addressed to Russia, following the adoption of the Council Regulation (EU) 2024/1745 of 24 June 202410 (amending Council Regulation (EU) No 833/2014 of 31 July 2014) concerning restrictive measures in view of Russia's actions destabilising the situation in Ukraine, legal entities established outside Russia but whose proprietary rights are directly or indirectly owned for more than 50% by a legal person, entity or body established in Russia are also not eligible to participate in any capacity.

- **Measures for the protection of the Union budget against breaches of the principles of the rule of law in Hungary** - Following the Council Implementing Decision (EU) 2022/2506, as of 15 December 2022, no legal commitments can be entered into with Hungarian public interest trusts established under the Hungarian Act IX of 2021 or any entity they maintain. Affected entities may continue to apply to calls for proposals and can participate without receiving EU funding, as associated partners, if allowed by the call conditions. However, as long as the Council measures are not lifted, such entities are not eligible to participate in any funded role (beneficiaries, affiliated entities, subcontractors, recipients of financial support to third parties, etc.). In case of multi-beneficiary grant calls, applicants will be invited to remove or replace that entity in any funded role and/or to change its status into associated partner. Tasks and budget may be redistributed accordingly.

- **Restrictions for the protection of European communication networks** - The protection of European communication networks has been identified as an important security interest of

[7] Please note that the EU Official Journal contains the official list and, in case of conflict, its content prevails over that of the EU Sanctions Map
[8] Please note that the EU Official Journal contains the official list and, in case of conflict, its content prevails over that of the EU Sanctions Map
[9] Commission guidelines No 2013/C 205/05 on the eligibility of Israeli entities and their activities in the territories occupied by Israel since June 1967 for grants, prizes and financial instruments funded by the EU from 2014 onwards (OJEU C 205 of 19.07.2013, pp. 9-11)
[10] OJ L 229, 31.7.2014, p. 1–11

the Union and its Member States[11]. For further information, please refer to the Horizon Europe, Work Programme 2025, General Annexes, B – Eligibility on page 14[12].

4.2.3 Entities eligible for funding

In accordance with the Horizon Europe Work Programme 2025 [13], to be eligible for funding, the applicant must be established in one of the eligible countries, i.e.:

- the Member States of the European Union, including their outermost regions;
- the Overseas Countries and Territories (OCTs) linked to the Member States; [14]
- countries associated to Horizon Europe; [15] or,
- certain low- and middle-income countries.[16]

Individuals cannot apply for funding under this call. Legal entities, which are established in countries not listed above will be eligible for funding if their participation is considered essential for implementing the action by the EIT.

4.2.4 Consortium composition

Consortia must meet the below conditions to be eligible for funding. Only consortia satisfying all the below criteria will move to the external evaluation stage.

- Consortia must include at least two legal entities independent from each other, and each legally established in a different country.
- Consortia must involve partners from at least two sides of the Knowledge Triangle (Industry, Education, Research). Representation from at least one industry organisation (SME, Industry partner, etc.) is mandatory.
- Consortia must be led by a Commercialising Entity (e.g. SME, large industry player, etc.) that possesses the business capabilities and legal rights to take the innovation to market and scale.

[11] European Council conclusions of 1 and 2 October 2020 (EUCO 13/20), point 11; Council Conclusions on the significance of 5G to the European Economy and the need to mitigate security risks linked to 5G, 14517/19.
[12] https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/wp-call/2025/wp-14-general-annexes_horizon-2025_en.pdf
[13] https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/wp-call/2025/wp-14-general-annexes_horizon-2025_en.pdf
[14] Entities from Overseas Countries and Territories (OCT) are eligible for funding under the same conditions as entities from the Member States to which the OCT in question is linked. See the Horizon Europe Programme Guide on the portal for a complete list of OCTs.
[15] Please see the Horizon Europe Programme Guide on the Funding and Tenders Portal for up-to-date information on the current list of and the position for Associated Countries: https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/guidance/programme-guide_horizon_en.pdf
[16] See the Horizon Europe Programme Guide on the Funding and Tenders Portal for a complete list of these countries. List of participating countries in Horizon Europe.

- If the Commercialising Entity is a micro or small enterprise,[17] the following requirements and definitions shall apply:
    - The entity is a legally registered for-profit entity.
    - The entity must have at least 4 full-time equivalent (FTE) employees compensated on a salaried basis and dedicated at least 50% of their total working time to the entity at the time of proposal submission, demonstrable through payroll records or employment contracts upon request.
    - The entity must have a CEO working full-time in the company at the time of proposal submission, demonstrable through payroll records or employment contracts upon request.
    - The Commercialising Entity must demonstrate a minimum level of financial traction prior to application, having raised at least EUR 500,000 in the past 3 years from external funding (revenue, equity, or other dilutive sources). Grants or non-dilutive sources do not count against this threshold.
    - The entity cannot have publicly traded shares or be in the process of an Initial Public Offering (IPO).

4.2.5 Innovation Maturity Level

At the time of proposal submission, the proposed solution must be at an Innovation Maturity Level (IML) of either IML 7 (Validation of Solution) or IML 8 (Approval & Launch) with an obtained CE mark and be preparing for entry into a new market within the activity timeframe. Solutions at earlier IML stages are ineligible.[18]

4.2.6 Project duration

Projects must not run longer than 15 months, with an effective start date on 01 January 2027.

4.3 Funding Conditions for Applications

4.3.1 Maximum EIT Health funding

Projects may request up to 650,000 EUR in EIT Health funding. If the Commercialising Entity of the project is a micro or small enterprise, it must be allocated no less than 400,000 EUR and no more than 500,000 EUR of grant funding from EIT Health.

4.3.2 Co-funding requirements

EIT Health will fund a maximum of 50% of the project's total costs, up to the maximum EIT Health funding described above. The consortium must secure the remaining 50% co-funding from other sources (non-EIT Health).

[17] According to the EU definition of an SME. To see if your organisation meets this definition please use this tool - SME Self-assessment | EU Funding & Tenders Portal

[18] Please refer to EIT Health's Healthcare Innovation Cycle Framework for more information on the required Innovation Maturity Level for this call: https://eithealth.eu/a-framework-for-innovation-in-healthcare/

Project's total costs = EIT Health funding + Co-funding.

4.3.3 Budget submission

To assess the co-funding requirement, the project budget submitted must include the total project costs, not just a budget covering the EIT Health funding.

4.4 Applicant Exclusion Criteria

Applicants will be excluded from participation in the Call and from the award if they are in one of the situations referred to in Article 138(1) of the EU Financial Regulation. Applicants may not participate in this call that are subject to EU administrative sanctions (i.e. exclusion) or are in one of the following exclusion situations that bar them from receiving EU grants:

- bankruptcy, winding up, affairs administered by the courts, arrangement with creditors, suspended business activities or other similar procedures (including procedures for persons with unlimited liability for the applicant's debts);
- they are in breach of social security or tax obligations (including if done by persons with unlimited liability for the applicant's debts);
- they are guilty of grave professional misconduct (including if done by persons having powers of representation, decision-making or control, beneficial owners or persons who are essential for the award/implementation of the grant);
- they are guilty of fraud, corruption, having links to a criminal organisation, money laundering, terrorism-related crimes (including terrorism financing), child labour or human trafficking (including if done by persons having powers of representation, decision-making or control, beneficial owners or persons who are essential for the award/implementation of the grant);
- they have shown significant deficiencies in complying with their main obligations under an EU procurement contract, grant agreement, prize, expert contract, or similar (including if done by persons having powers of representation, decision-making or control, beneficial owners or persons who are essential for the award/implementation of the grant);
- they are guilty of irregularities within the meaning of Article 1(2) of Regulation No 2988/9534 (including if done by persons having powers of representation, decision making or control, beneficial owners or persons who are essential for the award/implementation of the grant); or
- they have created under a different jurisdiction an entity with the intent to circumvent fiscal, social or other legal obligations in the country of origin or created another entity with this purpose (including if done by persons having powers of representation, decision-making or control, beneficial owners or persons who are essential for the award/implementation of the grant).
- Have misrepresented the information required as a condition for participating in the procedure or have failed to supply that information; or,
- were previously involved in the preparation of documents used in the award procedure where this entails a breach of the principle of equality of treatment, including distortion of competition, that cannot be remedied otherwise.

As evidence, the applicants (i.e. the activity leader and all the proposed partners participating in the applicant consortium) will have to submit a declaration of honour on exclusion criteria and absence of conflict of interest. Failure to provide adequate documentation may result in the exclusion of the applicants concerned.

4.5 Contracting Requirements for Successful Applicants

The following contracting obligations and requirements must be fulfilled by each member in the consortium of selected projects to receive funding.

- Signature of the Financial Support Agreement (FSA)
- Signature of the Project Grant Agreement (PGA)
- Having a registered and validated Participant Identification Code (PIC)[19]
- Signature of the EIT Health's Financial Sustainability Contribution Agreement by the Commercialising Entity of the project[20]
- Settlement of any open balance with EIT Health

All consortium members of selected applications must sign all the above agreements and complete all the necessary steps within three months before grant funding can be dispersed. Failure to do so may lead to EIT Health withdrawing the funding offer and selecting the next application in the final list of ranks.

4.5.1 Legal Entity and Financial Capacity Check

Successful applicants may go through a legal entity validation process known as the Partners Validation Service. This process requires a valid PIC code, organisations in the consortium without a valid PIC code may fail this validation process. This can lead to significant delays in the release of funding. The Partners Validation Service will request registration documents and a signed Declaration of Honour from the successful applicant. The validation may also include a check of the successful applicants by the EIT in the Early Detection and Exclusion System (EDES) of the European Commission.[21]

By submitting the proposal, the applicants confirm that they have stable and sufficient financial resources to successfully implement the proposals in which they participate. Applicants must have stable and sufficient resources to successfully implement the projects and contribute their share. In accordance with Article 27 of the Horizon Europe Regulation, the financial capacity shall be verified for the activity leader if the requested funding is equal or greater than 500,000 EUR. If there are grounds to doubt the financial capacity of an applicant, EIT Health shall also verify the financial capacity of the applicant, or of the activity leader even where the requested funding is below the threshold referred to

[19] Register your organisation in the EU Funding & tender opportunities portal to obtain the nine-digit Participant Identification Code (PIC number). If you do not know if your organisation already has a PIC number, you can verify directly on the EU Portal (click here) whether your organisation is already registered.
[20] See paragraph 3.6 on Financial Sustainability Conditions for further information
[21] The Partners Validation Service is a shared service used by all EIT KICs. The service is operated by EIT Urban Mobility.

above. If requested by EIT Health, successful applicants will go through a financial capacity check as part of the Partners Validation Service.

If, after the financial capacity check, an applicant financial capacity is considered not satisfactory, further information may be required and further measure(s) may be applied by the KIC:

- an enhanced financial responsibility regime,
- the financial capacity of the applicant may be structurally guaranteed by another legal entity/ies;
- prefinancing paid in instalments;
- the KIC may propose no prefinancing;
- the activities may be subject to additional monitoring and reporting based on an action plan;
- the KIC may request that the applicant is replaced or, if needed, reject the entire proposal.
- the KIC may request that the applicant is replaced or, if needed, reject the entire proposal.

4.6 Grant Payment Mechanism for Successful Applicants

Funding will be provided via the cost reporting model.[22] The disbursement of EIT funds to subgrantees (a subgrantee is a successful applicant) is made in two payments for each year of operation: the pre-financing payment and the annual-balance payment.

1. The pre-financing payment is made to each subgrantee for each project for each year. The first pre-financing payment will be made within three months following the signature of all contracts and kick-off of the project. A subgrantee will receive as many prefinancing payments as the number of projects it participates in each year. The pre-financing payment may amount to a maximum of 25% of the EIT financial support amount a subgrantee has been allocated in the grant management system for the year N (e.g. 2026 or 2027 or 2028 respectively) by the time of the execution of the payment. The exact percentage amount is communicated in due course to subgrantees by the time of the execution of the payment.

   For Small and Micro Enterprises that will be commercialising the solution, additional pre-financing payments will be established up to a yearly maximum of 80% of the annual EIT grant for each year.

2. The annual balance payment is released within three months of the cost reporting / cost check / CFS audit, and at the latest September of the year N+1. This payment is made to each subgrantee for each project. This means that a subgrantee receives one annual balance payment per project calculated using the total accepted EIT financial support amount and the sum of all pre-financing payments received for each project in which it has participated. This payment is contingent upon the result of the performance assessment during the reporting phase. Both payments are communicated in due time to the Master contact and Legal and Finance contacts registered in our grant management system.

[22] See Chapter 07 of the EIT Health Project Implementation Handbook - https://eithealth.eu/library-of-call-appendices/?id=296

Above and beyond the specific EIT Health rules of participation, all activities must comply with the relevant Horizon Europe and EIT financial and legal framework considerations.

For further details on project implementation and the disbursement of funding, please see the EIT Health Project Implementation Handbook.

4.7 Financial Sustainability Contribution Conditions for successful applicants

All projects awarded EIT Health funding must contribute to the long-term financial sustainability of EIT Health and its ecosystem.

As a condition of funding, the Commercialising Entity of an awarded project must enter into a Financial Sustainability Contribution Agreement with EIT Health. There are two types of agreements with different terms – the Grant to Option to Equity Agreement, and the Revenue Sharing Agreement. Which agreement is signed depends on the size of the Commercialising Entity.

This agreement extends beyond the project duration and may have implications for ownership, financing, revenues, and overall strategy. It is important that applicants verify company size, align with stakeholders, and ensure the selected model fits their long-term strategy. Applicants are expected to fully understand these implications before applying.

The Financial Sustainability Contribution Agreement is signed at the time of project contracting and is a pre-requisite to the release of any funding to the entire consortium.

4.7.1 Grant to Option to Equity Agreement for Micro and Small Enterprises

If the commercialising entity is a micro or small enterprise, the Financial Sustainability Contribution Agreement that will be signed as a condition of funding will be a Grant to Option to Equity Agreement. The way this mechanism works is:

- Funding is provided as a grant.
- In exchange, EIT Health receives options that convert into equity in the company at a later stage, either at a set maturity date or if certain predefined events occur (such as an acquisition or change of control).
- Conversion metrics are defined upon the occurrence of certain trigger events:
    - A qualified equity financing round (predefined minimum size, external investors, real equity issuance), or
    - Other predefined liquidity events (e.g., acquisition or change of control).
- The options have a maturity date; if no trigger occurs before, options are converted into equity.
- Conversion triggers, valuation logic and conditions are predefined upfront, non-negotiable, and linked to the company, not just the project.

You can read the term sheet of the Grant to Option to Equity agreement here.

4.7.2 Revenue Sharing Agreement for Medium and Large Enterprises

If the commercialising entity is a medium or large enterprise, the Financial Sustainability Contribution Agreement that will be signed as a condition of funding will be a Revenue Sharing Agreement. The way this mechanism works is:

- Funding is provided as a grant.
- The company commits to sharing a portion of revenues generated from project results, namely the commercialisation of the funded innovation.
- Revenue sharing is triggered once sales revenues exceed EUR 10,000 and are generated within a of maximum five years after project end.
- The total amount of revenue sharing payments is capped (equal to the total project funding received plus a min. 15% mark-up) and can be structured as:
    - Fixed annual payments, or
    - Revenue-based payments over a defined period for a maximum period of five years once triggered.
- Obligations continue after the project ends and require long-term planning.

Please find further information about the Revenue Sharing model here.

4.8 Project Performance Monitoring During and After the Funding Period

During the funding period, projects will undergo regular monitoring and reporting to track progress against the agreed-upon workplan and deliverables. Project reporting takes place every six months in order for EIT Health to maintain a good overview of the activities. Activity Leaders are asked to report the progress of their deliverables, milestones and KPIs in a dedicated online platform, along with submitting a bi-annual cost report to ensure eligibility of costs. EIT Health monitoring principles and obligations are governed by the Horizon Europe MGA, Annex 5.

4.8.1 Monitoring during the funding period

The performance monitoring process during funding period serves to either fast-track, support, redirect, or stop the activity in cases of improper implementation or severe underperformance. Each activity is required to fill in one year-end performance report for each calendar year of project duration. For example, a project spanning from June 2026 to December 2028 would have to fill in three separate reports; one for 2026, one for 2027, and one for 2028.

A final performance report will be complied at the end of the project and will be a compilation of all performance reports submitted. Performance reporting serves as the basis for activity monitoring, which may take place directly after a performance report has been submitted. As such the information provided in the performance report largely informs the monitoring meeting between the project consortia and representatives of EIT Health. Please refer to the Implementation Handbook for further information.

4.8.2 Post-funding monitoring

Post-funding monitoring is required for up to five years after activity closure, possibly longer if required by the Financial Sustainability Contribution-Agreements. Post-funding monitoring will be light in format and aims to capture the project's impact beyond the period of EIT Health funding. This helps identify success stories, capture key learnings, and evaluate the use of public funding against EIT Health's and Horizon Europe's strategic goals.

4.9 Fast Track Mechanism and Additional Project Funding

Projects selected under this Call that demonstrate exceptional performance and high strategic value may be eligible for additional funding from EIT Health via the Fast Track mechanism. EIT Health may, at its own discretion and subject to available budget, offer the opportunity of extra grant funding to projects in its portfolio to maximize the impact of EIT Health's portfolio and seize time-sensitive opportunities. Successful execution and completion of a project will not guarantee Fast Track funding. Eligibility is strictly reserved for projects or entities that:

- **Meet or Exceed Expectations:** Have successfully achieved all planned milestones and be on track to deliver on its Key Performance Indicators (KPIs).
- **Justify Necessity:** Can demonstrate a critical need for continued public funding to address specific market failures or regulatory hurdles (e.g., unexpected regulatory changes, opportunity to expand to high-impact patient populations).
- **Strategic Alignment:** Align with the specific strategic priorities of EIT Health at the time of the Fast Track decision.

4.9.1 Evaluation process for the Fast Track mechanism

To access additional support, existing projects in the EIT Health portfolio will be required to present their case for additional support and submit a workplan and demonstrate the expected impact of the additional support requested.

Fast-tracked proposals will be subject to a specialized, expedited evaluation procedure involving an assessment by EIT Health and independent external experts against standard Horizon Europe criteria (Excellence, Impact, Implementation) and financial sustainability contribution potential.

The new project proposal and budget would be considered and linked to the financial sustainability of the KIC with a renewed or fully new financial sustainability contribution agreement signed. This last step could lead to the need to perform an updated due diligence analysis and validation on those companies engaging in those agreements.

5 Application Process

All application materials must be submitted via the EIT Health application platform.

We strongly advise applicants to familiarise themselves with EIT Health application platform before beginning their application, and to begin the application process on the platform at least one week before the deadline.

5.1 Key Timeline

Milestone	Date	Description
Call Launch	**24 June 2026**	Publication of the Call Document and opening of the application process.
Call Presentation Webinar	**15 July 2026, 12.00 CEST**	Presentation of the Call scope, objectives, and application platform.
Application form opens	**15 July 2026**	The application platform opens for applicants to begin submitting proposals.
Q&A Sessions	**01 September 2026, 11.00 CEST**	Open Q&A session for applicants to ask questions before deadline.
Proposal Submission Deadline	**16 September 2026, 16.00 CEST**	Strict deadline for application submissions. Late submissions will not be considered.
Evaluation: Eligibility notification	**07 October 2026**	Yes/no decision on proposal meeting eligibility requirements.
Remote Evaluation outcome notification & invite to pitches	**28 October 2026**	Communication of remote evaluation results and invitation to a final pitching session for proposals with a score of >70%.
Evaluation: Pitches	**16-20 November 2026**	Online pitching sessions in front of a panel of external and internal evaluators.
Final Award Notification	**09 December 2026**	E-mail notification of final results
Standstill Period	**09 December 2026 – 09 January 2027**	Preparation of grant agreements
Project Contracting Launch	**09 January 2027**	Registration and validation of all applicants in the Grant Management System, signature of all agreements, and PIC number validation.
Start Date of Project Activities	**09 January 2027**	Official commencement of funded projects.

Applicants are expected to ensure their availability for the pitching sessions and to accept the pitching date and time assigned if invited to a pitching session. EIT Health will not be able to rearrange pitching slots according to the availability of applicants.

5.2 Use of Artificial Intelligence

Applicants may use generative AI tools to assist in drafting funding proposals. All AI-generated content must be handled with caution, responsibility, and full transparency. Below are EIT Health's guidelines that applicants should consider when using generative AI tools to build a proposal:

- **Review & validate:** Critically check AI output for factual accuracy, relevance, and alignment with the call's objectives.
- **Verify citations:** Cross-check any references suggested by AI; remove or correct any that are fabricated or incorrect.
- **Ensure originality:** AI may mirror existing sources—applicants must avoid plagiarism by properly attributing all material.
- **Respect IP & privacy:** Do not include copyrighted or proprietary material without authorization; review AI platform terms and avoid submitting confidential or sensitive data to AI tools, unless data protection standards (e.g. GDPR) are met.

Applicants remain entirely accountable for every part of their proposal, including AI-produced text.

6 Evaluation Process

6.1 Evaluation Criteria

Proposals will be assessed against criteria consistent with Horizon Europe standards and specific to the EIT Health mission and financial sustainability. The table below provides a description of these criteria, the evaluation stage at which they apply, and the respective weights of each criteria in their contribution to the final score of each stage.

6.1.1 Remote evaluation criteria

The below table details the evaluation criteria for the remote evaluation stage. To pass through to the pitch evaluations, applicants must score at least 10% of the total score in each evaluation criteria, and at least 70% overall.

Evaluation Criteria	Description	Weight
Excellence	The proposed innovation is technically and clinically novel and aligned with the scope of the Call. Focus on the unmet need, maturity of the innovation, scientific quality, inclusion of gender, and the quality of the technical/clinical development plan. Applications must demonstrate: • A strong alignment with the aims of the call and activities being called for. • A clear and substantial unmet patient and healthcare need. • An improved, unique, or novel solution exhibiting a clear patient benefit compared to what is on the market. • A robust evidence base • An accurate assessment of the current and forecasted IML levels. • A well-reasoned explanation of how gender has been accounted for in the project.	35%
Impact	The proposed innovation has the potential to create significant value for European citizens and healthcare systems. Focus on the ambition and feasibility of the projected results of the project, in particular the future launch to the market of the solution and the contribution to the 150,000-patient impact target. Applications must demonstrate:	30%

Evaluation Criteria	Description	Weight
	• A high-quality business strategy and commercial exploitation plan. • A high-quality Intellectual Property Strategy. • The desired impact is clear, ambitious, and achievable. • The key performance indicators are relevant to the desired impact, and are specific, measurable, and achievable.	
Quality and Efficiency of Implementation	The project management plan, consortium, and allocation of resources is appropriate and realistic. Focus on the strength of the Knowledge Triangle Integration and capabilities across the consortium, CE quality of the work plan, budget planning and risk assessment. Applications must demonstrate: • A clear, reasonable, and appropriate workplan • A suitable consortium with appropriate knowledge, skills, and experience to deliver the workplan. • A comprehensive and reasonable risk assessment • A reasonable and sufficient budget	35%

6.1.2 Pitches Evaluation Criteria for Micro and Small Enterprises

The below table details the evaluation criteria for the pitch evaluation stage for applications where the commercialising entity is a micro and small enterprise. To be considered for funding, applicants must score at least 10% of the total score in each evaluation criteria, and at least 70% overall.

Evaluation Criteria	Description	Weight
Excellence	The proposed innovation is technically and clinically novel and aligned with the scope of the Call. Focus on the unmet need, maturity of the innovation, scientific quality, inclusion of gender, and the quality of the technical/clinical development plan. Applications must demonstrate: • A strong alignment with the aims of the call and activities being called for. • A clear and substantial unmet patient and healthcare need. • An improved, unique, or novel solution exhibiting a clear patient benefit compared to what is on the market.	20%

	• A robust evidence base to date and a strong clinical development strategy. • A high quality, feasible clinical study plan. • An accurate assessment of the current and forecasted IML levels. • A well-reasoned explanation of how gender has been accounted for in the project.	
Impact	The proposed innovation has the potential to create significant value for European citizens and healthcare systems. Focus on the ambition and feasibility of the projected results of the project, in particular the future launch to the market of the solution and the contribution to the 150,000-patient impact target. Applications must demonstrate: • A high-quality business strategy and commercial exploitation plan. • A high-quality Intellectual Property Strategy. • The desired impact is clear, ambitious, and achievable. • The key performance indicators are relevant to the desired impact, and are specific, measurable, and achievable.	20%
Quality and Efficiency of Implementation	The project management plan, consortium, and allocation of resources is appropriate and realistic. Focus on the strength of the Knowledge Triangle Integration and capabilities across the consortium, CE quality of the work plan, budget planning and risk assessment. Applications must demonstrate: • A clear, reasonable, and appropriate workplan • A suitable consortium with appropriate knowledge, skills, and experience to deliver the workplan. • A comprehensive and reasonable risk assessment • A reasonable and sufficient budget	25%
KIC portfolio strategic fit and compliance with the financial sustainability principles	Criterion in this category will focus on the ability of the commercialising entity to fulfil the terms outlined in the Financial Sustainability Contribution Agreement. Specific areas include: • target market; • the business model; • commercial exploitation plan; • intellectual property strategy; • the commercialising entity's financial health, • investor traction; • management team capacity and capability; and, • commercial ownership structures.	35%

6.1.3 Pitches Evaluation Criteria for Medium and Large Enterprises

The below table details the evaluation criteria for the pitch evaluation stage for applications where the commercialising entity is a medium or large enterprise. To be considered for funding, applicants must score at least 10% of the total score in each evaluation criteria, and at least 70% overall.

Evaluation Criteria	Description	Weight
Excellence	The proposed innovation is technically and clinically novel and aligned with the scope of the Call. Focus on the unmet need, maturity of the innovation, scientific quality, inclusion of gender, and the quality of the technical/clinical development plan. Applications must demonstrate: • A strong alignment with the aims of the call and activities being called for. • A clear and substantial unmet patient and healthcare need. • An improved, unique, or novel solution exhibiting a clear patient benefit compared to what is on the market. • A robust evidence base • An accurate assessment of the current and forecasted IML levels. • A well-reasoned explanation of how gender has been accounted for in the project.	20%
Impact	The proposed innovation has the potential to create significant value for European citizens and healthcare systems. Focus on the ambition and feasibility of the projected results of the project, in particular the future launch to the market of the solution and the contribution to the 150,000-patient impact target. Applications must demonstrate: • A high-quality business strategy and commercial exploitation plan. • A high-quality Intellectual Property Strategy. • The desired impact is clear, ambitious, and achievable. • The key performance indicators are relevant to the desired impact, and are specific, measurable, and achievable.	20%
Quality and Efficiency of Implementation	The project management plan, consortium, and allocation of resources is appropriate and realistic.	25%

Evaluation Criteria	Description	Weight
	Focus on the strength of the Knowledge Triangle Integration and capabilities across the consortium, CE quality of the work plan, budget planning and risk assessment. Applications must demonstrate: • A clear, reasonable, and appropriate workplan • A suitable consortium with appropriate knowledge, skills, and experience to deliver the workplan. • A comprehensive and reasonable risk assessment • A reasonable and sufficient budget	
KIC portfolio strategic fit and compliance with the financial sustainability principles	Criterion in this category will focus on the ability of the commercialising entity to fulfil the terms outlined in the Financial Sustainability Contribution Agreement. Specific areas include: • target market; • the business model; • commercial exploitation plan; • intellectual property strategy; • the commercialising entity's financial health, • investor traction; • management team capacity and capability; and, • commercial ownership structures. • revenue projections	35%

6.2 Evaluation Process

The selection process is a single-stage submission followed by

6.2.1 Admissibility and eligibility, exclusion and selection stages

1. **Admissibility and Eligibility Check:** EIT Health staff will perform a formal verification of application admissibility and eligibility status according to the requirements of the Call. See section 4 on application conditions.

6.2.2 Evaluation of proposals

2. **Remote Evaluation:** Three external independent experts will evaluate each submitted application and provide feedback and a score based on the evaluation criteria stated in section 6.1.

   Up to 16 shortlisted candidates who score at least 70 / 100 will be invited to the online pitches.

3. **Online Pitching:** Teams are invited to pitch their proposals at an online pitch session to a panel five experts; three external independent experts and two EIT Health management staff.

   The external independent experts will not have reviewed any applications during the remote evaluation stage. Following the evaluation criteria (see section 6.1), each panel member will score proposals based on the submitted application, the pitch, and the answers provided during the question and answers section of the pitch session.

   Applicants are expected to ensure their availability for the pitching sessions and to accept the pitching date and time assigned if invited to a pitching session. EIT Health will not be able to rearrange pitching slots according to the availability of applicants.

4. **Ethical Legal Social Issues Review:** Independent experts will evaluate each project suggested for funding on the Ethical, Legal, and Social Issues (ELSI) to ensure that all elements in the proposal linked to critical ethical, legal and social considerations are well defined and addressed, thereby helping to de-risk the EIT Health portfolio.

5. **Final Selection notification:** EIT Health management makes the final funding decision based on expert recommendations, online pitching scores, and available funding. Only applicants with an online pitching score of at least 70/100 will be considered for funding. All applicants will be notified of the final outcome and receive feedback from each expert in accordance with the timetable in section 5.1 above.

6.3 Evaluation methodology

6.3.1 Remote evaluation methodology

Each application will be reviewed by a panel of three external experts in accordance with the evaluation criteria (section 6.1). Each application will receive a single score and feedback on the application from each panel member who reviewed the application. Final scores for each application will be out of 100 and are calculated by taking the mean of the three reviewers' scores.

Applications will then be ranked from highest scoring to lowest scoring. The top 16 applications that score 70 / 100 or more will then be selected to proceed to the online pitches.

6.3.2 Online pitching evaluation methodology

Up to 16 shortlisted candidates who score at least 70 / 100 in the previous remote evaluation step will be invited to the online pitches. Pitching sessions will consist of a pitch and a question and answers session. Each evaluation panel member will evaluate proposals based on a review of the submitted application, the pitch, and the answers to the question and answers session. The evaluation panel will consist of five experts; three external independent experts and two EIT Health management staff.

Each application will receive a single score and feedback on the application from each panel member. Final scores for each application will be out of 100 and are calculated by taking the mean of the five reviewers' scores.

Scores from the remote evaluation are not accounted for during the online pitches. Because the pitching sessions allow panel members to go into further detail into the application, it is possible that the online pitching feedback may differ from the remote evaluation feedback.

6.3.3 Evaluation final outcome

Following the online pitching sessions, applications will be ranked from highest scoring to lowest scoring based on the online pitching scores only. Up to the top six applications that score 70 / 100 will be selected for funding and invited to the contracting stage (paragraph 3.6).

6.4 Communication of evaluation results to applicants

6.4.1 Communication of evaluation results

Following the award decision, all applicants will be informed of the result in writing via email from the application platform. All applicants will receive their overall score, and feedback from each panel member. It is important that all emails with the @eithealth.eu domain are added to the safe senders list for all consortium members so that critical emails do not get sent to applicants' spam folder.

Applicants may request further clarification regarding the evaluation result via email. EIT Health will aim to reply to such requests within 15 days. Where this is not possible, EIT Health will inform the applicant requesting clarification with an estimated response time.

6.4.2 Requirements for selected proposals

If the proposal is selected, subsequent communications may include a set of recommendations or conditions as a result of the outcome of the evaluation. These requirements may not entail a substantial modification of the proposal.

Such communications will establish a clear and non-negotiable deadline for the submission of the adjusted proposals.

Should all conditions be met within the established deadline, EIT Health will initiate the financial support agreement preparation process/onboarding (e.g. legal entity validation, signature of Declaration of honour, if not yet provided, financial capacity check, if relevant).

If the applicant fails to comply with the provided recommendations/conditions or does not respond in the time allocated, EIT Health reserves the right to withdraw the conditional notification. Should this occur, EIT Health may decide to contact the following application in the final ranking list.

6.5 Standstill Period

Following final outcome notification, a standstill period will begin. During this time no contracts will be signed, however this time may be used to review and prepare contracts for signature from the final outcome notification.

6.6 Publication of Call Results

EIT Health may make available via its website, information on the call results and the recipients of funds from this call.

The following information shall be published, having due regard for the requirements of confidentiality and security, in particular the protection of personal data:

- the recipient's full legal name and the country where it is established;
- the amount committed and, in case of a commitment with multiple recipients, the breakdown of this amount per recipient where available;
- subject of grant or contract.

7 Grounds for Appeal and Appeal Procedure

Applicants may appeal the outcome of their application of their own proposal in line with the EIT Health Appeals procedure. The only grounds for appeal are as follows:

- Process errors.
- Technical problems beyond the control of applicants (e.g. the technical failure of the electronic submission system).
- Human/technical errors made by EIT Health staff.
- If you consider that you have been adversely affected by a particular decision not following EIT Health's Code of Conduct.

What does NOT constitute grounds for an appeal:

- Scores awarded in the course of the proposal evaluation process (unless these go against our Code of Conduct).

7.1.1 Appeals Procedure

- Applicants should send their appeals in writing to appeals@eithealth.eu as soon as they identify an error, but no later than 21 days after the relevant outcome notification.
- EIT Health assesses the claim and delivers a first response
- If there are grounds for appeal, EIT Health will attempt to remedy the consequences (e.g. if a technical error of EIT Health prevented the submission of a proposal or application, a late submission may still be accepted as eligible)
- The Compliance Manager, and where applicable, Supervisory Board is notified about the matter if:
    - the applicant does not accept a rejection of the appeal, or
    - there are grounds for appeal, but the problem cannot be remedied any more without disrupting the process

8 Where to Get Help

We aim to make the application process as clear and accessible as possible. If you have questions regarding this call for proposals, please consult the following resources:

8.1 Call Information Webinars

We offer two distinct online sessions to guide applicants:

Session	Purpose	Date & Access
Call Presentation Webinar	Comprehensive introduction to the Call's objectives, scope, and the funding model.	**15 July 2026 12.30 CEST** **Click here to register**
Final Q&A Session	A dedicated session to answer specific, detailed questions from applicants who are finalising their proposals.	**01 September 2026, 11.00 CEST** **Click here to register**

8.2 Frequently Asked Questions (FAQ)

A comprehensive Frequently Asked Questions (FAQ) document is available, covering common questions on eligibility, budget preparation, and the evaluation process. We recommend consulting this document before submitting your formal application.

- **Access Link:** FAQ Document

8.3 Contact for Support

For general administrative queries, questions about the application platform, or technical issues with the submission process, please contact the EIT Health directly:

- **Email:** calls@eithealth.eu – please include the call code: INNO_UPTAKE and your application reference code in the subject line of all correspondence.

9 Other Terms and Conditions

9.1 Acceptance of the call conditions

EIT Health reserves the right to make reasonable amendments and additions to the call conditions. Amendments and additions to the call conditions shall be valid only before the submission deadline, and if made available to all potential applicants at the same time via this call document and any relevant call documents.

EIT Health may declare the call unsuccessful in the case where zero applications are received, if the applications do not meet the admissibility, eligibility, exclusion and selection criteria, or if none of the applications reach the score thresholds laid down in this call text.

By submitting the application form, the applicant agrees to the present call conditions. Applicants agree that they have no legal entitlement to funding.

9.2 Cancellation of the call

EIT Health reserves the right to cancel the call at any time before the signature of the Financial Support Agreement(s) without the obligation to compensate applicants, in particular where its objectives can no longer be met, provided that the applicants are informed in a transparent manner in writing as follows:

- if the cancellation takes place before that award: on the call page of https://eithealth.eu/
- if the cancellation takes place following the communication of the results to the applicants, during the standstill period, or anytime before the signature of the Financial Support Agreement: in writing directly to the selected applicants.

9.3 Data Protection

EIT Health ensures that any processing of personal data shall be performed in accordance with Regulation (EU) 2016/679 of the European Parliament and of the Council of 27 April 2016, on the protection of natural persons with regard to the processing of personal data and on the free movement of such data, and in accordance with Directive 95/46/EC (General Data Protection Regulation). As a data subject, you have the right of access, the right to rectification, the right to erasure, the right to restrict processing, the right to data portability, the right to object, and the right not to be subject to a decision based solely on automated processing. If you have a question about personal data processing or want to exercise your data subject rights, you can contact our Data Protection Officer at DataPrivacy@eithealth.eu.

The collected personal data will be used solely for the evaluation of the applications and the conduct of the call process. The data controller is EIT Health.

Personal data will be deleted five years after the announcement of the results of the call in case of unsuccessful applications and seven years for successful applicants.

By submitting your application to this call, you consent that EIT Health will collect, transfer, process, store, and delete your data in accordance with the aforementioned conditions.

For more information on the processing of your personal data as part of an application to this call, please consult the Legal notice and Terms of use of EIT Health's online application management platform. You can also read EIT Health's online privacy statement at: https://eithealth.eu/privacy-policy/.

9.4 Confidentiality

EIT Health undertakes to use any confidential information shared by the applicants solely for the purposes of the evaluation process.

Confidential information shall mean data and/or information (in any form) that is proprietary to, or possessed by, the applicants and not generally known to the public, or that has not yet been revealed whether in tangible or intangible form, that is identified as confidential in writing or when disclosed orally.

Confidential information included in the application form must be expressly labelled by the applicant as such in the form. As regards confidential information expressly labelled as such in the call process, EIT Health undertakes to (i) not disclose them in any way and any form, without the prior written authorization of the applicant; and (ii) not to use them for purposes other than those strictly necessary for participation in the call.

Confidential information may be shared among EIT Health and its subsidiaries (e.g. KIC Co-Location Centres) solely for the purposes of the call process. EIT Health undertakes to impose this confidentiality obligation on its employees and the employees of its subsidiaries and its collaborators, as well as on independent experts and all subjects who, by virtue of participating in the conduct of the call, including as members of the Evaluation Committee, may have access to such confidential data and information.

The applicants agree that data and information regarding the selected projects' implementation (e.g. success stories) not labelled as confidential may be disclosed in connection with the activities of EIT Health.

9.5 Avoidance of conflict of interest

EIT Health is committed to ensure the avoidance of conflict of interest (regarding all actors) and comply with the principles of transparency, non-discrimination and sound financial management. As such, EIT Health staff and members of the EIT Health Managing Boards (Supervisory Board) cannot be involved in submitted proposals.

Measures to avoid potential Conflict of Interest or unequal treatment of applicants are ensured including through appropriate conflict of interest declaration and assessment process, established written communication channels and independent and fair complaints/redress procedures.

In case an applicant becomes aware of a potential conflict of interest affecting the conduct of the call process, it shall notify the EIT Health of the conflict of interest without any delay.

9.6 Ethics and values

The proposal must comply with:

- ethical principles (including the highest standards of research integrity); and,
- applicable EU, international and national law, including the Charter of Fundamental Rights of the European Union and the European Convention for the Protection of Human Rights and Fundamental Freedoms and its Supplementary Protocols.

No financial support/ funding can be granted, within or outside the EU, for activities that are prohibited in all Member States. No financial support/ funding can be granted in a Member State for an activity which is forbidden in that Member State.

Please refer to the financial support agreement for further requirements.

9.7 Intellectual property rights

Applicants retain full and exclusive ownership of their prior information and intellectual property rights. By submitting their application, applicants confirm that they own or lawfully hold, and have secured or will secure in due time, all rights and permissions necessary to use all elements of the innovative product or service included in their application, or that they will take appropriate measures to secure and protect such rights during the project. Applicants agree to indemnify and hold harmless EIT Health, the EIT, and/or any assignee or affiliate from any third-party allegations or claims of intellectual property rights infringement by the product or service of applicants. Applicants shall have the right to further develop, use and license their intellectual property rights for creating, making, marketing, and distributing products, services, and technology. Applicants agree to respect the IPR (Intellectual Property Rights) Rules (Article 16) of the Model Grant Agreement and Article 10 of the Financial Support Agreement (Common Subgrant Agreement Model).

9.8 Withdrawal of the funding – Recovery of undue amounts

EIT Health may withdraw the funding after its award and recover all payments made in line with the provisions of the Financial Support Agreement (Article 7.4.), including in the following cases:

- in case the applicant committed substantial errors, irregularities or fraud;
- in case the applicant committed serious breach of obligations under the Financial Support Agreement or during its award (including non-compliance with the call conditions, submission of false information, failure to provide required information, etc.)
- it is established that the awarded applicants were not eligible or should have been excluded.

9.9 Checks, reviews, audits and investigations

EIT Health retains the right to initiate checks, reviews and audit on an applicant that has been awarded funding, to verify compliance with the requirements of the call conditions and of the legal and contractual framework referred to above.

EIT Health may request any information and data from applicants that have been awarded funding for five years after completion for these purposes, as well as in relation to monitoring by the EIT.

In accordance with the Grant Agreement between the EIT and the KIC as well as the Financial Support Agreement, the EIT and/or the Commission, the European Anti-Fraud Office (OLAF), the European Public Prosecutor's Office (EPPO) and the Court of Auditors may carry out checks, reviews, audits and investigations in relation to the call and the implementation of the projects.

9.10 Applicable law

The present call is governed by the applicable European Union legal framework (i.e. in particular the EIT Regulation[23], the EU Financial Regulation[24], the Horizon Europe Regulation[25]), supplemented if necessary by the national law of Belgium.

The applicants agree to observe the obligations outlined in the Partnership Agreement and the Grant Agreement signed between the EIT and EIT Health. Applicants agree to comply with the terms of the Model Financial Support Agreement between successful applicants and EIT Health, available here.[26]

9.11 Settlement of disputes

All disputes arising out of or in connection with this Agreement, which cannot be solved amicably, shall be finally settled before the courts of Brussels.

[23] Regulation (EU) 2021/819
[24] Regulation (EU, Euratom) 2024/2509
[25] Regulation (EU) 2021/695
[26] See the folder 'Contract Templates'.

10 About the EIT

The European Institute of Innovation and Technology (EIT) is a European Union body with a legal personality and a wide legal capacity accorded to legal persons under national law. The EIT was created in 2008 by the European Union (EU) to enhance Europe's global competitiveness by fostering collaboration between businesses, research institutions, and higher education organizations.

The EIT is governed by Regulation (EU) 2021/695 (EIT Regulation), which aligns the EIT's mission with the EU's priorities and the objectives of Horizon Europe on evolving research, innovation, economic growth, job creation, global competitiveness, sustainable growth, higher education and entrepreneurship, by means of the Knowledge and Innovation Communities (KICs), which address specific societal challenges and are established and supported by the EIT.

The EIT Strategic Innovation Agenda (SIA) 2021-2027 is aligned with Horizon Europe and lays down the priority fields and the strategy of the EIT for future initiatives, capacity to generate the best innovation added-value, objectives, key actions, mode of operation, expected results, impact, as well as an estimate of the resources needed for the duration of Horizon Europe.

Horizon Europe Regulation

The Horizon Europe Regulation (EU) 2021/695 foresees that the EIT takes part in the implementation of the Horizon Europe Programme in accordance with its strategic objectives for the period 2021 to 2027, as laid down in the Strategic Innovation Agenda of the EIT, and taking into account the strategic planning of Horizon Europe.

10.1 EIT and Knowledge and Innovation Community (KIC) relations

The EIT Regulation defines KICs, such as EIT Health, as large-scale Institutionalised European Partnerships of higher education institutions, research organisations, companies and other stakeholders in the innovation process in the form of a strategic network, regardless of its legal form, based on joint mid- to long-term innovation planning to meet the EIT's challenges and contribute to attaining the objectives established.

According to the EIT Regulation, and without prejudice to the partnership agreements and grant agreements between the EIT and each KIC, the KICs have substantial autonomy to establish their internal organisation and composition, as well as their agenda and working methods, provided that they result in progress towards achieving the objectives of the EIT and the KICs, taking into account the strategic planning of Horizon Europe and the strategic direction of the EIT set out in the SIA and by the Governing Board.

10.2 Contractual framework between the EIT and the KICs

The long-term relations between the EIT and each KIC are based on a seven-year Partnership Agreement (PA)[27] laying down the general terms and conditions under which the KIC operates as an Institutionalised European Partnership. Subject to positive performance, interim review and outcome of

[27] Model Partnership Agreement: Partnership Agreement

comprehensive assessment of the KIC, the PA can be extended for another period of a maximum of seven years.

The Partnership Agreement between the EIT and EIT Health entered into force on 01 January 2016.

The Grant Agreement (GA)[28] is the contractual instrument laying down the provisions concerning the implementation of the KIC activities (KIC Business Plan, Cross-KIC activities, etc.) through grants, on an annual or multi-annual basis of up to three years with the KICs. Business plans describe the main objectives and expected results and actions taken by the KICs.

The Grant Agreement (2026-2028) between the EIT and EIT Health will enter into force during 2026 and have a retroactive date as of 01 January 2026. The signature of the grant agreement between EIT and EIT Health is a requirement for the disbursement of funding through this call.

In accordance with the Grant Agreement (Annex 5), the KIC launches calls (i.e. open calls or KIC partnership calls) in order to select projects or award prizes. The KIC awards a "financial support to third parties" (i.e. the so called "subgrants" and "prizes") for the implementation of these projects and signs subgrant agreements ("Financial Support Agreements") with the selected entities or consortia.

[28] Horizon Europe Model Grant Agreement: general-mga_horizon-euratom_en.pdf

11 About EIT Health

11.1 Vision and mission

EIT Health was established in 2015, as a 'knowledge and innovation community' (KIC) of the European Institute of Innovation and Technology (EIT) as strong, diverse and balanced European Partnership of best-in-class organisations in education, research, technology, business creation and corporate and social innovation.

EIT Health's vision is 'To enable people in Europe to live longer, healthier lives by building and growing businesses to create products and services that progress healthcare in Europe, while strengthening our economy and the sustainability of our healthcare systems.'

EIT Health's mission is: 'By 2030, we'll be Europe's leading innovation platform, facilitating longer, healthier lives and more sustainable healthcare systems.

11.2 Strategic Objectives

Strengthening healthcare systems in Europe

We want to overcome obstacles to innovation so we can improve healthcare delivery in Europe and make life-changing solutions possible. By working together,
we can remove barriers across borders to create a more resilient and dynamic European healthcare system.

Promoting better health of citizens

European citizens and patients sit at the center of our organisation. That's why we're engaging people at every stage; raising awareness, sharing knowledge and creating tools, treatment and breakthrough solutions which will promote healthy living and active ageing.

Contributing to a sustainable health economy in Europe

We want to create a fertile environment in which innovation can flourish. By building health enterprises and bringing innovative products and services to market, we can create new jobs to grow and strengthen a sustainable European economy.